Table 3.
Summary of ADVANCE Data (mean 5 years of follow-up) showing occurrence of specified microvascular events in those in the Intensive versus the Standard glucose control groups. [Patel et al. 2008].
| Measure | N Events in Intensive Group (N = 5571) | N Events Standard Group (N = 5569) | Intensive Risk Ratio per 100 | Standard Risk Ratio per 100 | Difference in Risk Ratio | NNT** | 95% CI for NNT |
|---|---|---|---|---|---|---|---|
| Major Microvascular Events composite measure | 526 | 605 | 9.44 | 10.86 | −1.42 | 70.3* | 39.3–332.7 |
| New or Worsening Nephropathy | 220 | 292 | 3.94 | 5.24 | −1.30 | 77.3* | 48.3–193.4 |
| New Onset Microalbuminuria | 1318 | 1434 | 23.66 | 25.75 | −2.09 | 47.8* | 27.1–204.0 |
| New or Worsening Retinopathy | 332 | 349 | 5.96 | 6.27 | −0.31 | n.s. | |
| Visual Deterioration | 3033 | 3015 | 54.44 | 54.14 | +0.03 | n.s. | |
| New or Worsening Neuropathy | 2353 | 2311 | 42.24 | 41.50 | +0.74 | n.s. |
*
Significant at p < 0.05 or lower.
**
Over a 5-year follow-up period.
NNT, number needed to treat; n.s., not significant (for associations that are not significant, it is not appropriate to estimate NNT).